Skip to main content
Clinical Trials/NCT00240851
NCT00240851
Completed
Phase 4

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating Acetaminophen Extended Release Caplets (3900 mg/Day) in the Treatment of Post-Race Muscle Aching and Pain (Soreness)

Johnson & Johnson Consumer and Personal Products Worldwide0 sites665 target enrollmentOctober 18, 2005

Overview

Phase
Phase 4
Intervention
acetaminophen extended release
Conditions
Pain
Sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Enrollment
665
Primary Endpoint
The average change from baseline in muscle soreness on Day 1
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to compare the effectiveness of acetaminophen extended release caplets to placebo in treating the muscle aching and pain (soreness) that occurs after a marathon.

Detailed Description

This is a randomized, double-blind, placebo-controlled study to compare the effectiveness and safety of acetaminophen and placebo in treating muscle aching and pain (soreness) that occurs in subjects who complete a marathon. Subjects are randomized to receive acetaminophen extended release caplets, 3900 mg/day (two 650 mg caplets taken three times a day, for four days) or placebo (two placebo caplets taken three times a day, for four days). The primary measurement of efficacy is the average change from baseline in muscle soreness, on Day 1, the day of the marathon. Safety assessments consist of monitoring adverse events, and a physical examination at the screening visit, including vital signs, weight, a medical history review, and a urine pregnancy test for females of childbearing potential. The hypothesis of the study is that acetaminophen is more effective than placebo in the relief of post-race muscle aching and pain (soreness) score on the evening of the race. Two acetaminophen 650 mg extended release caplets, taken by mouth, three times a day over a four day period or two placebo caplets, taken by mouth, three times a day over a four day period.

Registry
clinicaltrials.gov
Start Date
October 18, 2005
End Date
February 2004
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients must be able to comply with the study schedule
  • be able to swallow the study medication
  • complete the marathon
  • not take any analgesics after completing the marathon and before their eligibility to participate in the study has been determined
  • rate their muscle soreness at least a 4, on a 0 - 10 point scale

Exclusion Criteria

  • Previous diagnosis of osteoarthritis
  • currently have or have had a medical condition that may be relevant in one's eligibility to participate in the study
  • known hypersensitivity to acetaminophen
  • unable to understand or follow the instructions for the study
  • taken any investigational medication within 30 days of the marathon

Arms & Interventions

001

acetaminophen extended release

Intervention: acetaminophen extended release

Outcomes

Primary Outcomes

The average change from baseline in muscle soreness on Day 1

Secondary Outcomes

  • Average change from baseline in muscle soreness for both morning and evening assessments, combined and separately; Average ratings of interference with 1) sleep, 2) daily activity, and 3) ability to go for a run

Similar Trials